References
- Hochberg J, Cairo M S. Tumor lysis syndrome current perspective. Haematologica 2008; 93: 9–12
- Kalemkerian G P, Darwish B, Varterasian M L. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 1997; 103: 363–367
- Baeksgaard L, Sorenson J B. Acute tumor lysis syndrome in solid tumors: a case report and review of the literature. Cancer Chemother Pharmacol 2003; 51: 187–192
- San Miguel J F, Almeida J, Orfao A. Laboratory investigations'. Myeloma, Mehta J, Singhal S. Martin Dunitz, London 2002; 243–268
- Terpos E, Politou M, Rahemtulla A. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol 2004; 130: 623–625
- Sezer O, Vesole D, Singhal S, Richardson P, Stadtmauer E, Jacob C, et al. Bortezomib-induced tumour lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma 2006; 7: 233–235
- Fassas A B, Desikan K R, Siegal D, Golper T A, Munshi N C, Barlogi B, et al. Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haematol 1999; 105: 938–941
- Richardson P G, Barlogi B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase II study of bortezomib in refractory and relapsed myeloma. N Engl J Med 2003; 348: 2609–2617
- Karin M, Cao Y, Florian R, Greten F R, Zhi-Wei L. NF-kappa in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 4: 301–310
- Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530–1534
- Millenium Pharmaceuticals. Velcade for Injection [summary of product characteristics]. Millenium Pharmaceuticals, Cambridge, MA 2006
- Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
- Kenealy M K, Prince H M, Honemann D. Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma. Pharmacotherapy 2006; 26: 1205–1206
- Jaskiewicz A D, Herrington J D, Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukaemia. Pharmacotherapy 2005; 25: 1820–1825
- Chim C S. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumour lysis syndrome. Cancer Chemother Pharmacol 2008; 62: 181–182